Sees FY25 operating expenses $92M-$95M. Management also outlined its long-range plan of becoming the recognized ...

Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...

Rockville’s MaxCyte has made its first acquisition in its more than quarter-century of operation. It’s keeping its eyes out ...

U.S. Physical Therapy, Inc. operates outpatient physical ... performance optimization and ergonomic assessments. U.S. The company was founded in 1990 and is headquartered in Houston, TX.

The company's anti-wrinkle therapy Botox Cosmetic generated $687M in net revenue, a ~5% YoY drop, while its therapeutic version added $873M, a ~13% YoY increase, both exceeding Street forecasts.

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

NeuroPace provided initial financial guidance targets for 2025: Revenue of $92 million – $96 million, representing growth of 15.5% – 20.5% versus the midpoint of the expected 2024 revenue range of $79 ...

“In 2024 we grew our business with four products in five indications globally, exceeding the updated revenue guidance we ... launch of our first gene therapy, in Sanfilippo syndrome, and to ...